OBJECTIVES: Since Behçet syndrome (BS) is the prototype of inflammation-induced thrombosis, immunosuppressants are recommended in place of anticoagulants. Here we assessed the clinical efficacy and the corticosteroid-sparing effect of adalimumab (ADA)-based treatment versus DMARDs in a large retrospective cohort of patients with BS-related venous thrombosis. METHODS: We retrospectively collected data from 70 BS patients treated with DMARDs or ADA-based regimens (ADA ± DMARDs) because of venous complications. Clinical and imaging evaluations were performed to define vascular response. We explored differences in outcomes between ADA-based regimens and DMARDs, with respect to efficacy, corticosteroid-sparing role and time on treatment. We also evaluated the role of anticoagulants as concomitant treatment. RESULTS: After a mean follow-up of 25.7±23.2 months, ADA-based regimens induced clinical and instrumental improvement of venous thrombosis more frequently (p=0.001) and rapidly (p<0.0001) than DMARDs. The mean dose of corticosteroids administered at the last follow-up was significantly lower in the ADA-based regimens than in the DMARDs one (p<0.0001). The time on treatment was significantly longer in ADA-based regimens than in the DMARDs one (p=0.002). No differences were found in terms of efficacy and time on treatment between DMARDs or ADA-based regimens among subjects receiving anticoagulants and those who did not. CONCLUSIONS: In this large retrospective study we have shown that ADA-based regimen is more effective and rapid in inducing resolution of venous thrombosis in BS patients than DMARDs, allowing reduction of steroid exposure. Moreover, our findings suggest that anticoagulation does not modify the efficacy on venous complications of either ADA-based regimens or DMARDs. This article is protected by copyright. All rights reserved.

Adalimumab-based treatment versus DMARDs for venous thrombosis in Behçet syndrome. A retrospective study of 70 patients with vascular involvement / Emmi, Giacomo; Vitale, Antonio; Silvestri, Elena; Boddi, Maria; Becatti, Matteo; Fiorillo, Claudia; Fabiani, Claudia; Frediani, Bruno; Emmi, Lorenzo; Scala, Gerardo Di; Goldoni, Matteo; Bettiol, Alessandra; Vaglio, Augusto; Cantarini, Luca; Prisco, Domenico. - In: ARTHRITIS & RHEUMATOLOGY. - ISSN 2326-5191. - 70:9(2018), pp. 1500-1507. [10.1002/art.40531]

Adalimumab-based treatment versus DMARDs for venous thrombosis in Behçet syndrome. A retrospective study of 70 patients with vascular involvement

Goldoni, Matteo;Vaglio, Augusto;
2018

Abstract

OBJECTIVES: Since Behçet syndrome (BS) is the prototype of inflammation-induced thrombosis, immunosuppressants are recommended in place of anticoagulants. Here we assessed the clinical efficacy and the corticosteroid-sparing effect of adalimumab (ADA)-based treatment versus DMARDs in a large retrospective cohort of patients with BS-related venous thrombosis. METHODS: We retrospectively collected data from 70 BS patients treated with DMARDs or ADA-based regimens (ADA ± DMARDs) because of venous complications. Clinical and imaging evaluations were performed to define vascular response. We explored differences in outcomes between ADA-based regimens and DMARDs, with respect to efficacy, corticosteroid-sparing role and time on treatment. We also evaluated the role of anticoagulants as concomitant treatment. RESULTS: After a mean follow-up of 25.7±23.2 months, ADA-based regimens induced clinical and instrumental improvement of venous thrombosis more frequently (p=0.001) and rapidly (p<0.0001) than DMARDs. The mean dose of corticosteroids administered at the last follow-up was significantly lower in the ADA-based regimens than in the DMARDs one (p<0.0001). The time on treatment was significantly longer in ADA-based regimens than in the DMARDs one (p=0.002). No differences were found in terms of efficacy and time on treatment between DMARDs or ADA-based regimens among subjects receiving anticoagulants and those who did not. CONCLUSIONS: In this large retrospective study we have shown that ADA-based regimen is more effective and rapid in inducing resolution of venous thrombosis in BS patients than DMARDs, allowing reduction of steroid exposure. Moreover, our findings suggest that anticoagulation does not modify the efficacy on venous complications of either ADA-based regimens or DMARDs. This article is protected by copyright. All rights reserved.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11381/2845261
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 32
  • ???jsp.display-item.citation.isi??? 37
social impact